Researchers are learning more about ways to predict the likelihood of newborn complications from early in pregnancy using samples provided by the Indiana University School of Medicine Building Blocks of Pregnancy Biobank.
Researchers at Indiana University School of Medicine have published their work about a specific type of childhood cancer in the peer-reviewed, international oncology journal, Cancers. This research involves a combination therapy that significantly slows tumor growth in models, which includes a model established from cells taken from tumors donated by Tyler Trent.
Alexander G. Robling, PhD, a professor, researcher and leader at Indiana University School of Medicine has been selected to chair the school’s Department of Anatomy, Cell Biology and Physiology. His new appointment beings January 1, 2021.
Researchers at Indiana University School of Medicine are testing use of tezampanel, a novel antagonist at glutamate receptors that could treat opioid withdrawal syndrome and other addictions and mental illnesses.
As researchers around the world work feverishly to discover a vaccine in the battle to prevent COVID-19, Indiana University School of Medicine has been selected as a site for a vaccine trial. Biopharmaceutical company AstraZeneca, in partnership with Oxford University, is moving forward with its late-stage clinical trial for a vaccine known as AZD1222.
INDIANAPOLIS -- A researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center has been awarded a five-year, $5.7 million National Cancer Institute grant to evaluate long-term health outcomes for cancer patients who receive platinum-based chemotherapies. An internationally recognized expert on cancer survivorship, Lois B. Travis, MD, ScD, leads the ongoing study that could lessen cancer treatment side effects for millions of patients.
In honor of Indiana University’s bicentennial, IU School of Medicine is awarding 11 highly accomplished students with four-year scholarships and inclusion in a leadership development program involving the school’s top executives and esteemed faculty.
A veteran researcher and Indiana University School of Medicine faculty member will be taking on a new role with the Indiana Biosciences Research Institute—a leading industry-inspired applied research institute. Alan Palkowitz, PhD, was named the new president and CEO of the IBRI in an announcement on Wednesday, September 2. Palkowitz will spend 80 percent of his time at the IBRI serving in this new position, while maintaining his role at IU School of Medicine as a senior research professor of medicine and leader of the IUSM-Purdue TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Center.